Bibliography
- KIM MS, KWON HJ, LEE YM et al.: Histone deacetylases induce angiogenesis by negative regulation of tumour suppressor genes. Nat. Med. (2001) 7:437–443.
- FOLKMAN J: Anti-angiogenesis: new concept for therapy of solid tumours. Ann. Surg. (1972) 175:409–416.
- GRAY SG, EKSTROM TJ: The human histone deacetylase family. Exp. Cell Res. (2001) 262:75–83.
- MARKS PA, RICHON VM, RIFKIND RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. j Natl. Cancer Inst. (2000) 92:1210–1216.
- MAGNER WJ, KAZIM AL, STEWART Cet al.: Activation of MHC class I, II and CD40 gene expression by histone deacetylase inhibitors. I bronurrol. (2000) 165:7017–7024.
- TAKAHIRO M, TOWATARI M, KOSUGI H etal.: Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood (2000) 96:3847–3856.
- SEMENZA GL: Hypoxia, clonal selection and the role of HIF-1 in tumour progression. Grit. Rev Biochern. Ma. Biol. (2000) 35:71–103.
- FERRARA N, DAVIS-SMYTH T: The biology of vascular endothelial growth factor. Endocr. Rev (1997) 18:4–25.
- KWON HJ, OWA T, HASSIG CA: Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc. Natl. Acad. Sri. USA (1998) 95:3356–3361.
- OIKAWA T, ONOZAWA C, INOSE M: Depudecin, a microbial metabolite containing two epoxide groups, exhibits anti-angiogenic activity in vivo. Biol. Pharrn. Bull. (1995) 18:1305–1307.